In the News
In the News
Janssen and Johnson & Johnson spokespeople are providing regular updates to UK media on our response to the COVID-19 pandemic
June 12 - Professor Hanneke Schuitemaker speaks to Sky News
Professor Hanneke Schuitemaker, our Global Head of Viral Vaccine Discovery and Translational Medicine, spoke on Ian King Live about our accelerated initiation of the Phase 1/2a first-in-human clinical trials of our investigational SARS-CoV-2 vaccine.
Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.
Hanneke also touched on how Johnson & Johnson’s efforts to expedite the development and production of a SARS-CoV-2 vaccine are enhanced by a collaboration between Janssen and the Biomedical Advanced Research and Development Authority (BARDA).
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
March 31 - Dr Paul Stoffels speaks to Sky News
We remain committed to addressing the global COVID19 crisis.
Today, our Chief Scientific Officer Dr Paul Stoffels spoke to Sky News about our announcement of a lead vaccine candidate and plans to initiate human clinical studies by September.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
March 13 - Professor Hanneke Schuitemaker on The Science Media Centre Panel
Taking a united approach to combat coronavirus
On March 13, Janssen was invited to take part in a Science Media Centre media briefing on the development of potential treatments for coronavirus (COVID-19), held in London.
Here, Professor Hanneke Schuitemaker, our Global Head of Viral Vaccine Discovery and Translational Medicine, and Disease Area Stronghold Leader for Viral Vaccines, spoke about our multi-pronged approach to combat COVID-19.
On January 29, we announced that we were mobilising resources to develop a vaccine candidate to protect against COVID-19, while also initiating screening of our library of antiviral therapies.
To further accelerate our vaccine research programme and accelerate the discovery of potential COVID-19 therapies, we have expanded our partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health & Human Services. Together, we are hopeful we can identify a vaccine candidate for this virus and start Phase 1 clinical studies within approximately 8-12 months.
We hope that a vaccine candidate can ultimately be deployed quickly and extensively to help combat this outbreak.
Our philosophy is that global health security is everyone’s responsibility and requires coordinated effort from governments, civil society and healthcare companies. We are committed to working alongside these organisations to identity and develop effective vaccines and/or therapies against COVID-19.
As ever, we are driven by our Credo – our top priority remains our patients, customers and employees. We will remain on the front lines of this health crisis, bringing our full resources and minds to combat it.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
March 6 - Johan Van Hoof live on BBC News
As a leader in global health, Johnson & Johnson is on the front line of the coronavirus (COVID-19) health crisis, bringing our full resources and minds to combat it.
Today our Global Head of Vaccines, Johan Van Hoof spoke to BBC News about our efforts to accelerate the development of a vaccine.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Job Code: CP-167516 Date of preparation: July 2020